交易 Kalaris Therapeutics INC - KLRS 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.3
• 長倉隔夜倉息調整: -0.02151%
• 短倉隔夜倉息調整: -0.00071%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 10
• 保證金: 5.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 5.35
• 開倉: 5.37
• 1 年變化: -36.67%
• 日區間: 5.37 - 5.41

交易 Kalaris Therapeutics INC - KLRS 差價合約

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company''s lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi''s sarcoma, primary effusion lymphoma, and multicentric Castleman''s diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.